PROSTATE-SPECIFIC ANTIGEN FORMS COMPLEXES WITH HUMAN alpha 2-MACROGLOBULIN AND BINDS TO THE alpha 2-MACROGLOBULIN RECEPTOR/LDL RECEPTOR-RELATED PROTEIN

Abstract

Quantifying free PSA and PSA-ACT complexes, as routinely done in managing prostate-associated diseases, does not represent the total secretion capacity of the prostate. The proteinase inhibitor alpha 2-M has to be considered as a main contributor to PSA complex formation in the blood.